Company Overview of Hovione FarmaCiencia SA
Hovione FarmaCiencia SA develops and manufactures active pharmaceutical ingredients (APIs) and intermediate drug products for the pharmaceutical industry in the United States and other North American countries, Europe, and Japan. The company specializes in chemistry and particle engineering. It offers services related to the development, manufacture, and pre-formulation of new chemical entities and existing APIs for off-patent products; NavStream, a read only Internet based management tool that enables selective access to GMP data referent to development project or production line at Hovione; and project management services. The company also provides custom synthesis services in the areas of...
Founded in 1959
Key Executives for Hovione FarmaCiencia SA
Chief Executive Officer and Director
Chief Financial Officer and Vice President of Finance
Vice President of Sales & Business Development and President of Us Operations
Head of Particle Design Sciences In New Jersey
Director of Corporate Communications
Compensation as of Fiscal Year 2014.
Hovione FarmaCiencia SA Key Developments
Hovione Appoints Filipe Gaspar as Vice President R&D
Jan 12 15
Hovione announced the appointment of Dr. Filipe Gaspar as Vice President of its Research and Development organization. Dr. Gaspar will lead teams based in Lisbon and New Jersey that serve clients' drug development projects; he will also be defining long-term product development strategies and collaborations. He will report to Guy Villax, Hovione's Chief Executive. Dr. Gaspar joined Hovione in 2003 as a Manufacturing engineer and later became responsible for the technical leadership of spray drying technology. In 2004 Dr. Gaspar moved to R&D to start the Particle Engineering group, there he was involved in more than 120 projects from preclinical stage to commercial. During that period he was the Lead Scientist in four projects that reached commercial stage, including the first at Hovione submitted under Quality by Design. He was instrumental in many of the projects that have contributed to Hovione's growing success in Particle Engineering. In 2012 he moved to a Business Development role and spent a year based in New Jersey.
Hovione Submits First Investigational New Drug Application for Minocycline to United States Food and Drug Administration
Dec 1 14
The United States Food and Drug Administration has received Hovione's first investigational new drug application for minocycline gel to administer topically for acne. The filing is a part of the company's strategy to develop improved drug delivery options for established drugs. After receiving United States Food and Drug Administration's acceptance of the investigational new drug application submission, the firm plans to commence human clinical phase I/II trials in early 2015.
Anacor Pharmaceuticals, Inc. Enters Into Manufacturing Agreement with Hovione FarmaCiencia SA
Oct 3 14
On September 30, 2014, Anacor Pharmaceuticals Inc. entered into a manufacturing agreement with Hovione FarmaCiencia SA, pursuant to which Hovione will manufacture and supply to the company Tavaborole active pharmaceutical ingredient (API) for the company's drug KERYDINTM (tavaborole) topical solution, 5%. Pursuant to the agreement, the company is obligated during the term to purchase from Hovione a portion of its API requirements for KERYDIN intended for distribution in the United States. The company may qualify and, subject to certain limitations, purchase a portion of its API requirements for KERYDIN from an alternate supplier during the term of the Agreement. The purchase price for the API is fixed subject to potential periodic adjustment over the term of the agreement. The agreement will continue for an initial term expiring on December 31, 2020 and is subject to automatic 18-month renewal terms, unless earlier terminated by either party on at least 18 months' written notice prior to the end of the initial term (or any such renewal term) or for specified events under the agreement. Either party may terminate the agreement for uncured material breaches by the other party or in the event of the bankruptcy or insolvency of the other party. In addition, the company may terminate the agreement in the event that KERYDIN's new drug application is withdrawn or Hovione is unable, in certain circumstances, to satisfy the company's purchase requirements. Prior to January 31, 2018, Hovione may give notice to the company to terminate the agreement effective December 31, 2018 in the event that the company does not make aggregate purchases of API for KERYDIN from Hovione in excess of a certain minimum amount.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|